SERAMIDLARNING NOALKOGOL JIGAR YOG'LI KASALLIGINI ERTA TASHXISLASH VA PROGNOZLASHDAGI DIAGNOSTIK-PROGNOSTIK AHAMIYATI: ROC- VA REGRESSION-TAHLIL NATIJALARI

Murodjon Nasirdinov; Zuhriddin Salohiddinov

Авторы

Murodjon Nasirdinov ijon davlat tibbiyot instituti, Oilaviy shifokorlarni tayyorlash kafedrasi assistenti Автор
Zuhriddin Salohiddinov Andijon davlat tibbiyot instituti, Oilaviy shifokorlarni tayyorlash kafedrasi mudiri tibbiyot fanlari doktori professor Автор

Ключевые слова:

noalkogol jigar yog'li kasalligi, seramid, ROC-tahlil, logistik regressiya, ordinal regressiya

Аннотация

Noalkogol jigar yog'li kasalligini (NJYK) erta va kam invaziv usullar bilan tashxislash zamonaviy gepatologiyaning hal etilmagan muammolaridan biri bo'lib qolmoqda. Ushbu maqolada qon zardobidagi seramid ko'rsatkichining NJYKni tashxislash va prognozlashdagi diagnostik-prognostik ahamiyati ROC-tahlil hamda binar logistik va ordinal regressiya modellari asosida baholangan. Tadqiqotga 84 nafar shaxs (nazorat guruhi - 29, steatoz guruhi - 28, steatogepatit guruhi - 27 nafar) jalb etilib, seramid darajasi HPLC-MS usuli bilan aniqlangan. ROC-tahlil natijalariga ko'ra, seramid NJYKni aniqlashda yuqori diagnostik aniqlikka ega bo'ldi (AUC=0,932; cut-off ≥11,71 u.b.; sezuvchanlik 81,8%, spetsifiklik 93,1%). Binar logistik regressiyada seramid yakka modelda mustaqil ahamiyatli prediktor bo'lgan (OR=1,232; 95% CI: 1,092-1,391; p=0,0007), yosh, jins va tana vazni indeksi (TVI) qo'shilgandan so'ng modelning to'g'ri tasniflash darajasi 96,4% gacha oshgan. Ordinal regressiya tahlilida seramid steatoz (OR=1,166; p=0,0026) va fibroz (OR=1,042; p=0,0030) darajalari bilan mustaqil bog'liq prediktor sifatida saqlanib qolgan. Olingan natijalar asosida seramid, TVI va lipid spektri ko'rsatkichlarini birlashtirgan amaliy diagnostik-prognostik model taklif etildi.

##plugins.themes.default.displayStats.downloads##

##plugins.themes.default.displayStats.noStats##

Библиографические ссылки

1. Hannun Y.A., Obeid L.M. Sphingolipids and their metabolism in physiology and disease // Nature Reviews Molecular Cell Biology. - 2018. - Vol. 19, № 3. - P. 175-191.

2. Younossi Z.M., Koenig A.B., Abdelatif D. et al. Global epidemiology of NAFLD - meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. - 2016. - Vol. 64, № 1. - P. 73-84.

3. Srivastava A., Jong S., Gola A. et al. Cost-comparison analysis of FIB-4, ELF and FibroScan in community pathways for non-alcoholic fatty liver disease // BMC Gastroenterology. - 2019. - Vol. 19. - P. 122.

4. Eslam M., Sanyal A.J., George J. et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease // Gastroenterology. - 2020. - Vol. 158, № 7. - P. 1999-2014.

5. O'Donnell V.B., Dennis E.A., Wakelam M.J.O., Subramaniam S. LIPID MAPS: serving the next generation of lipid researchers with tools, resources, data, and training // Science Signaling. - 2019. - Vol. 12. - eaaw2964.

6. Daminov B.T., Usmanova U.Sh., Alavi B.A., Sobirova G.N. Прогноз распространённости неалкогольной жировой болезни печени // European Journal of Molecular & Clinical Medicine. - 2020. - Vol. 7, № 3. - P. 3535-3538.